We aim to create and commercialise new technologies that solve intractable problems in neuroscience and neuromedicine.
Brain disorders affect nearly 15% of the population, and yet the vast majority of new neurotechnologies never make it out of the lab. We develop first-in-class technologies that can be deployed widely to accelerate neuroscience and reduce the number of people suffering from brain disorders. To do so, we combine our core technical competency in neuroengineering with an expertise in biotechnology entrepreneurship that is unique among academic labs, allowing us to identify more important unmet needs and deploy solutions more rapidly.
Our first projects address major unmet needs in drug delivery, diagnostics, and multiomics. We are developing a new generation of viral vectors to allow gene therapies to be delivered to the human brain without brain surgery, to enable a new generation of cures for autism, epilepsy, and neurodegeneration. We are developing a new platform technology for mapping the cell-type and circuit organization of the brain at the single-cell level, so that we can identify and understand subtypes of schizophrenia and depression and develop more targeted therapies. Finally, we are building a medical device that will allow for rapid and minimally invasive sampling of the cerebrospinal fluid, with the goal of enabling everyone to get an annual, risk-free liquid biopsy for Alzheimer’s disease.